ZOLGENSMA is a gene replacement therapy for spinal muscular atrophy (SMA).¹

Steps to treatment

For single-dose intravenous infusion only

Administer ZOLGENSMA to patients who are clinically stable in their overall baseline health status. Postpone infusion in patients with infections until the infection has resolved and the patient is clinically stable. Clinical signs or symptoms of infection should not be evident at the time of ZOLGENSMA infusion.¹ 

ZOLGENSMA is a suspension administered as an intravenous infusion over 60 minutes. A programmable syringe pump should be used to infuse the full volume of ZOLGENSMA. The recommended dose of ZOLGENSMA is 1.1 × 10¹⁴ vector genomes per kilogram (vg/kg) of body weight.¹

All patients should receive systemic corticosteroids prior to and following ZOLGENSMA infusion.

The recommended treatment regimen is detailed in the Prescribing Information and on the After Treatment page of this website. Prophylactic corticosteroid treatment is required to help manage potential increases in liver aminotransferases following infusion with ZOLGENSMA.¹

See the preparation, dosing, and infusion process for ZOLGENSMA